Topical lidocaine and capsaicin 8% are the two topical options with the clearest evidence behind them for neuropathic foot pain. Which one fits depends on what is driving the neuropathy, not on how the burning feels. The American Academy of Pain Medicine brought together an expert panel. The panel reported strong evidence and high consensus that capsaicin 8% is effective for diabetic peripheral neuropathy and for postherpetic neuralgia (nerve pain after shingles). It also reported moderate evidence with high consensus that lidocaine is likely effective for diabetic peripheral neuropathy, idiopathic neuropathy and postsurgical neuropathy.1
The other side matters just as much. A Cochrane review looked at topical lidocaine in adults with chronic neuropathic pain. It found only 12 studies covering 508 participants in total, all judged at high risk of bias. It concluded that there was no good-quality randomized evidence to support its use.2 Topicals change the signal at the skin and nerve surface. They do not change what is damaging the nerve.
What to know before you try a topical
- Topicals modulate the signal, not the driver. The burning is an alarm. The alarm keeps ringing while the real problem goes on.
- The evidence is condition-specific. Support for lidocaine and for capsaicin 8% is tied to named diagnoses. It is not tied to “neuropathy” as a category.
- Peripheral neuropathy is a category, not a diagnosis. Metabolic, nutritional, autoimmune, toxic and structural drivers are often stacked in the same patient.
- Testing changes decisions. On-site electrodiagnostic testing (EMG/NCS) helps show which fibers are involved. That comes before a plan is built around a product.
How does topical lidocaine work on neuropathic foot pain?
Lidocaine is a local anesthetic (numbing drug). Put on the skin, it quiets the nerve endings under the area it covers. That can lower the burning or shooting pain in that patch of skin.
It does not reach the cause. It does not improve flow through the small vessels that feed the nerve. It does not correct a nutritional deficiency. It does not slow the metabolic chemistry that damaged the fiber in the first place.
Where the support is, and where it is not
The American Academy of Pain Medicine panel gave lidocaine its strongest rating for postherpetic neuralgia. There it found strong evidence and high consensus that lidocaine is effective. For diabetic peripheral neuropathy, idiopathic neuropathy and postsurgical neuropathy, the rating was lower. It was moderate evidence with high consensus that lidocaine is likely effective.1
Read the Cochrane finding alongside that, not instead of it. Twelve small trials in 508 adults is a thin evidence base. Thin evidence is a reason to set expectations carefully. On its own, it is not a reason to rule out a low-risk option.2 Your prescribing clinician decides whether a prescription or over-the-counter topical belongs in your plan.
When is the capsaicin 8% patch the right topical?
Capsaicin works through a different pathway than lidocaine, and its labeled use is narrower. Qutenza (capsaicin 8% patch) is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet.
The evidence rating tracks the label closely. The same expert panel found strong evidence and high consensus for capsaicin 8% in diabetic peripheral neuropathy and postherpetic neuralgia. It gave weaker ratings for other nerve pain conditions.1
What “applied in clinic” means
At Regenerve, a clinician applies the capsaicin 8% patch. It is not sent home with you. It is not repeated more often than every three months.
That spacing is part of how the treatment is designed. It is one more reason the diagnosis has to be settled before the patch is scheduled. Our page on the Qutenza capsaicin 8% patch describes what the visit itself involves.
Why does the cause of your neuropathy decide which topical to use?
Patients often arrive with a list of creams, patches and counterirritants (products that create a competing sensation) found online. The list is not the problem. The problem is that it is built around the feeling, not the cause, so two people with the same burning end up on the same products for entirely different diseases.
We work the other way around. We start from which driver is doing the most damage right now.
- Metabolic pattern. Say the pattern and history fit diabetic peripheral neuropathy of the feet. Then both lidocaine and capsaicin 8% sit inside their evidence-supported ground. For capsaicin 8%, that ground is also FDA-labeled.
- Nutritional pattern. The history may point to B12 deficiency or a gluten-related process. Then a topical may make the nights easier while the real correction happens elsewhere.
- Chemotherapy-related pattern. Symptom tools may still have a role. But the priority is finding out whether large fiber, small fiber or mixed involvement is present.
- Autoimmune or structural pattern. Topicals alone are the weakest choice here. That is because inflammation and poor blood flow (impaired perfusion) keep the nerve irritable no matter what is on the skin.
Testing that changes the decision
Regenerve does electrodiagnostic testing (EMG/NCS) on site. It measures how large fibers carry signals. That helps separate a whole-body driver from a single pinched spot (focal compression). It also tells us whether the symptom picture and the wiring picture agree.
When unsteadiness or dizziness is also part of the story, VNG is available. VNG is a diagnostic test of inner-ear balance, not a treatment. It is used to find out whether the balance problem sits in the vestibular (inner-ear balance) system and not in the feet.
What to bring to your visit
Your clinician needs more than “it burns.” Pattern, timing and history are what narrow the list.
- Where it is: toes, forefoot, midfoot or the whole foot, and whether both sides are equally affected.
- When it is worst: especially whether it wakes you at night.
- What it feels like: burning, tingling, electric shocks, numbness, or pain from light touch, such as a bedsheet.
- Your history: diabetes or prediabetes, chemotherapy, and alcohol use. Also celiac or gluten sensitivity, weight-loss (bariatric) or other gut surgery, known B12 status, and any toxic exposures.
- What has already been tested: past EMG/NCS results, and whether anyone has raised small fiber involvement.
Start with the Nerve Damage Score
The Nerve Damage Score is five questions, and it is free. It is built to find which driver is most likely doing the damage in your case. That way the talk about topicals starts from a diagnosis, not a product list. We do not promise that nerve damage can be regenerated or reversed.
Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134. Call (314) 886-5739 or text (314) 886-5902, or email info@regenerve.com. We are minutes from St. Louis Lambert International Airport. We see patients from across the St. Louis region, Missouri and Illinois, including Edwardsville, Glen Carbon, Collinsville, Troy and Maryville.
When a topical alone is not enough, the next questions are usually about duloxetine for painful diabetic neuropathy or what to expect at a Qutenza patch visit.
Frequently asked questions
Is topical lidocaine worth trying for burning feet at night?
It is reasonable to discuss when your pain pattern matches a condition where lidocaine has support. It carries little whole-body risk. Treat it as symptom modulation. Pair it with a workup of what is driving the burning, because the relief stops when the patch does. See why feet burn at night.
Does topical lidocaine help diabetic peripheral neuropathy of the feet?
The American Academy of Pain Medicine panel rated lidocaine as likely effective for diabetic peripheral neuropathy. The rating rests on moderate evidence with high consensus. It does not address the metabolic and small-vessel injury underneath. That is where the rest of the plan goes. See diabetic peripheral neuropathy treatment in St. Louis.
Is the capsaicin 8% patch an option if my neuropathy is not diabetic?
Qutenza is FDA-approved in adults for postherpetic neuralgia and for diabetic peripheral neuropathy of the feet. Whether it fits another neuropathy depends on the driver your workup finds. A clinician applies it in the clinic. It is repeated no more often than every three months. See the hidden drivers of peripheral neuropathy.
Why do topicals help less when I have small fiber neuropathy?
Small fiber involvement causes burning, hot-coal feelings and changed temperature sense. These can be widespread, not limited to the patch of skin a topical covers. Standard nerve conduction studies may also look normal. That is why the workup has to match the symptom pattern. See small fiber neuropathy symptoms and testing.
Should I get nerve testing before trying a topical?
Not necessarily before, but testing changes what comes after. Electrodiagnostic testing shows which fibers are affected. That narrows the list of likely drivers. It also tells us whether a topical is a bridge or a distraction. See treatment options for peripheral neuropathy in the feet.
What is the most effective topical treatment for neuropathy in the feet?
Topical lidocaine and capsaicin 8% have the clearest evidence behind them. An American Academy of Pain Medicine expert panel rated capsaicin 8% effective for diabetic peripheral neuropathy on strong evidence. It rated lidocaine likely effective on moderate evidence. Which one fits your feet depends on what is driving the neuropathy, not on how the burning feels, so the cause gets found first.
Which is better for neuropathy, lidocaine or capsaicin?
Neither wins across the board. Lidocaine is a local anesthetic that calms the nerve endings under the skin it covers. Its support includes diabetic, idiopathic and postsurgical neuropathy. The capsaicin 8% patch works through a different pathway. It is FDA-approved only for postherpetic neuralgia and diabetic neuropathy of the feet. It is applied in the clinic no more often than every three months. Your diagnosis decides.
Is there a neuropathy cream that actually works?
Some topicals lower the burning in the patch of skin they cover. But the research is thinner than the store shelf suggests. A Cochrane review found only 12 studies of topical lidocaine, covering 508 adults, all at high risk of bias. A cream changes the signal at the skin. It does not change what is damaging the nerve, so it works best as one part of a plan built around the cause.
Sources
- American Academy of Pain Medicine. Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician. Pain Medicine. 2026. AAPM clinical guideline summary
- Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2014. PMID 25058164